Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a trial of Ateronon in Patients with Coronary Disease to Evaluate its Effectiveness in Assessing the Risk Factors of Atherosclerosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Omicron Pharmaceuticals

Criteria

Inclusion Criteria:

• Men and Women with demonstrated Coronary Disease

• AtheroAbzyme positive during screening process

• Elevated Total Cholesterol

• Willingness to take study nutritional supplement once a day for 3 months

Exclusion Criteria:

• Women who are pregnant, nursing or intend pregnancy during the period of treatment

• Known milk, soy or whey allergy